InsiderTrades.com logo
War Over Taiwan? Protect Your Wealth NOW
From Behind the Markets   |   Ad
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
Access my report now >>>

EPI Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$233,482.46
Insider Selling (Last 12 Months): C$5,549.14

ESSA Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at ESSA Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ESSA Pharma Share Price & Price History

Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 12/1/2017 09:15 PM ET

This chart shows the closing price history over time for EPI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
War Over Taiwan? Protect Your Wealth NOW
From Behind the Markets   |   Ad
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
Access my report now >>>

ESSA Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2024Peter VirsikDirectorSell1,718C$3.23C$5,549.14
11/21/2023Franklin Milan BergerDirectorBuy23,529C$5.73C$134,821.17
11/3/2023Franklin Milan BergerDirectorBuy16,471C$5.99C$98,661.29
See Full Table
War Over Taiwan? Protect Your Wealth NOW
From Behind the Markets   |   Ad
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
Access my report now >>>

SEC Filings (Institutional Ownership Changes) for ESSA Pharma (TSE:EPI)

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.
Read More on ESSA Pharma

Today's Range

Now: N/A

50 Day Range

MA: C$0.32
Low: C$0.32
High: C$0.32

52 Week Range

Now: N/A

Volume

4,700 shs

Average Volume

68,239 shs

Market Capitalization

C$9.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ESSA Pharma?

ESSA Pharma's top insider shareholders include:
  1. Franklin Milan Berger (Director)
  2. Peter Virsik (Director)
Learn More about top insider investors at ESSA Pharma.
War Over Taiwan? Protect Your Wealth NOW
From Behind the Markets   |   Ad
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
Access my report now >>>